<DOC>
	<DOCNO>NCT00055146</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness ONTAK previously treat patient chronic lymphocytic leukemia ( CLL )</brief_summary>
	<brief_title>Study ONTAK Patients With B-Cell Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<criteria>Patients Bcell Chronic Lymphocytic Leukemia , Rai Stage 0II indication treatment NCI Working Group Criteria Rai Stage III IV . Patients must receive least one prior purine analoguebased chemotherapy regimen . ECOG Performance Status 0 , 1 , 2 . Female patient pregnant must use birth control course study three week study end . Prior treatment ONTAK ( DAB389IL2 ) DAB486IL2 . Received therapy CLL within 35 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>